EKF Diagnostics Holdings plc
("EKF", the "Company")
Investor results briefing update
As stated on the 4 March 2020, EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, will announce its preliminary results for the year ended 31 December 2019 on Tuesday 24 March 2020.
A briefing open to all investors was meant to take place on Tuesday 24 March 2020. The decision has been made by the management team to cancel this event. Instead the results presentation will be made available on the Company's website to download here: https://www.ekfdiagnostics.com/documents-reports.html
If you have any questions, please contact the team at Walbrook PR on 0207 933 8780 or at [email protected].
EKF Diagnostics Holdings plc |
www.ekfdiagnostics.com |
Christopher Mills, Non-Executive Chairman |
Tel: 029 2071 0570 |
Julian Baines, CEO |
|
Richard Evans, FD & COO |
|
|
|
N+1 Singer (Nomad & Broker) |
Tel: 020 7496 3000 |
Aubrey Powell / George Tzimas / Carlo Spingardi (Corporate Finance) Tom Salvesen (Corporate Broking) |
|
|
|
Walbrook PR Limited Tel: 020 7933 8780 or [email protected] |
Paul McManus/ Lianne Cawthorne |
Mob: 07980 541 893 / 07584 391 303 |
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.
